Communities That HEAL Intervention and Mortality Including Polysubstance Overdose Deaths: A Randomized Clinical Trial.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 Oct 2024
Historique:
medline: 21 10 2024
pubmed: 21 10 2024
entrez: 21 10 2024
Statut: epublish

Résumé

The HEALing Communities Study (HCS) evaluated the effectiveness of the Communities That HEAL (CTH) intervention in preventing fatal overdoses amidst the US opioid epidemic. To evaluate the impact of the CTH intervention on total drug overdose deaths and overdose deaths involving combinations of opioids with psychostimulants or benzodiazepines. This randomized clinical trial was a parallel-arm, multisite, community-randomized, open, and waitlisted controlled comparison trial of communities in 4 US states between 2020 and 2023. Eligible communities were those reporting high opioid overdose fatality rates in Kentucky, Massachusetts, New York, and Ohio. Covariate constrained randomization stratified by state allocated communities to the intervention or control group. Trial groups were balanced by urban or rural classification, 2016-2017 fatal opioid overdose rate, and community population. Data analysis was completed by December 2023. Increased overdose education and naloxone distribution, treatment with medications for opioid use disorder, safer opioid prescribing practices, and communication campaigns to mitigate stigma and drive demand for evidence-based interventions. The primary outcome was the number of drug overdose deaths among adults (aged 18 years or older), with secondary outcomes of overdose deaths involving specific opioid-involved drug combinations from death certificates. Rates of overdose deaths per 100 000 adult community residents in intervention and control communities from July 2021 to June 2022 were compared with analyses performed in 2023. In 67 participating communities (34 in the intervention group, 33 in the control group) and including 8 211 506 participants (4 251 903 female [51.8%]; 1 273 394 Black [15.5%], 603 983 Hispanic [7.4%], 5 979 602 White [72.8%], 354 527 other [4.3%]), the average rate of overdose deaths involving all substances was 57.6 per 100 000 population in the intervention group and 61.2 per 100 000 population in the control group. This was not a statistically significant difference (adjusted rate ratio [aRR], 0.92; 95% CI, 0.78-1.07; P = .26). There was a statistically significant 37% reduction (aRR, 0.63; 95% CI, 0.44-0.91; P = .02) in death rates involving an opioid and psychostimulants (other than cocaine), and nonsignificant reductions in overdose deaths for an opioid with cocaine (6%) and an opioid with benzodiazepine (1%). In this clinical trial of the CTH intervention, death rates involving an opioid and noncocaine psychostimulant were reduced; total deaths did not differ statistically. Community-focused data-driven interventions that scale up evidence-based practices with communications campaigns may effectively reduce some opioid-involved polysubstance overdose deaths. ClinicalTrials.gov Identifier: NCT04111939.

Identifiants

pubmed: 39432308
pii: 2825142
doi: 10.1001/jamanetworkopen.2024.40006
doi:

Banques de données

ClinicalTrials.gov
['NCT04111939']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2440006

Auteurs

Bridget Freisthler (B)

Ohio State University College of Social Work, Columbus.

Rouba A Chahine (RA)

RTI International, Research Triangle Park, North Carolina.

Jennifer Villani (J)

National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.

Redonna Chandler (R)

National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.

Daniel J Feaster (DJ)

University of Miami Miller School of Medicine, Miami, Florida.

Svetla Slavova (S)

University of Kentucky, Lexington.

Jolene Defiore-Hyrmer (J)

State of Ohio Board of Pharmacy, Columbus.

Alexander Y Walley (AY)

Boston Medical Center, Boston, Massachusetts.

Sarah Kosakowski (S)

Boston Medical Center, Boston, Massachusetts.

Arnie Aldridge (A)

RTI International, Research Triangle Park, North Carolina.

Carolina Barbosa (C)

RTI International, Research Triangle Park, North Carolina.

Sabana Bhatta (S)

New York State Department of Health, Albany.

Candace Brancato (C)

University of Kentucky, Lexington.

Carly Bridden (C)

Boston Medical Center, Boston, Massachusetts.

Mia Christopher (M)

RTI International, Research Triangle Park, North Carolina.

Tom Clarke (T)

Substance Abuse and Mental Health Services Administration, Rockville, Maryland.

James David (J)

Columbia University, New York, New York.

Lauren D'Costa (L)

RTI International, Research Triangle Park, North Carolina.

Irene Ewing (I)

University of Cincinnati College of Medicine, Cincinnati, Ohio.

Soledad Fernandez (S)

Ohio State University Department of Biomedical Informatics and Center for Biostatistics, Columbus.

Erin Gibson (E)

Boston Medical Center, Boston, Massachusetts.

Louisa Gilbert (L)

Columbia University, New York, New York.

Megan E Hall (ME)

RTI International, Research Triangle Park, North Carolina.

Sarah Hargrove (S)

University of Kentucky, Lexington.

Timothy Hunt (T)

Columbia University, New York, New York.

Elizabeth N Kinnard (EN)

Boston Medical Center, Boston, Massachusetts.

Lauren Larochelle (L)

Massachusetts Department of Public Health, Dorchester.

Aaron Macoubray (A)

RTI International, Research Triangle Park, North Carolina.

Shawn Nigam (S)

University of Kentucky, Lexington.

Edward V Nunes (EV)

Columbia University Irving Medical Center, New York, New York.

Carrie B Oser (CB)

University of Kentucky, Lexington.

Sharon Pagnano (S)

Massachusetts Department of Public Health, Dorchester.

Peter Rock (P)

University of Kentucky, Lexington.

Pamela Salsberry (P)

Ohio State University College of Public Health, Columbus.

Aimee Shadwick (A)

Recovery Ohio, Columbus.

Thomas J Stopka (TJ)

Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts.

Sylvia Tan (S)

RTI International, Research Triangle Park, North Carolina.

Jessica L Taylor (JL)

Boston Medical Center, Boston, Massachusetts.

Philip M Westgate (PM)

University of Kentucky, Lexington.

Elwin Wu (E)

Columbia University, New York, New York.

Gary A Zarkin (GA)

RTI International, Research Triangle Park, North Carolina.

Sharon L Walsh (SL)

University of Kentucky College of Medicine, Center on Drug and Alcohol Research, Lexington.

Nabila El-Bassel (N)

Columbia University, New York, New York.

T John Winhusen (TJ)

University of Cincinnati College of Medicine, Cincinnati, Ohio.

Jeffrey H Samet (JH)

Boston Medical Center, Boston, Massachusetts.

Emmanuel A Oga (EA)

RTI International, Research Triangle Park, North Carolina.

Classifications MeSH